1. Scrip
  2. >>Business
  3. >>Deals

PureTech Cashes In On Promise Of Karuna Schizophrenia Drug

Gets $100m Upfront From Royalty Pharma

 
• By Kevin Grogan

Karuna’s KarXT could be the first new mechanism for treating schizophrenia approved in more than 50 years and founder PureTech is tapping into that promise by linking up with Royalty Pharma and boosting its cashpile.

Zohar_Daphne.1200
CEO Daphne Zohar • Source: PureTech

PureTech Health plc is reaping the benefits of the excitement surrounding the schizophrenia candidate KarXT from Karuna Therapeutics, Inc., one of the companies it founded, with the sale of royalty rights that could bring in up to $500m to advance its own pipeline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

 
• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

More from Business

Roche US Exports To Exceed Imports After New $50bn Investment

 
• By Andrew McConaghie

A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus

 
• By Mandy Jackson

Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.